Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
First Investment: 2021
By quantifying a cell’s genome, proteome, transcriptome, and other “omes” all at once — that is, by doing multiomics — investigators can find new disease biomarkers and new drug targets. Cellanome is combining its team’s expertise in sequencing, microfluidics, sensors, synthetic biology, and informatics to build a multiomics platform that measures biological events at unprecedented resolution and scale.
Explore Companies
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules